More FDA Discipline Review Letters Could Improve PDUFA, Firms Say
This article was originally published in The Tan Sheet
Executive Summary
Pharma industry representatives urge changes to FDA program to increase application review transparency and communication between agency and NDA sponsors. Stakeholders spoke at a meeting for an interim assessment of enhanced review transparency and communication established under PDUFA V.